I'd rather the company follow in the steps of Regeneron. That stock was trading at $15/share five years ago and now it's hovering around $340. I can hold my several thousand shares for awhile in anticipation of a nice ride up. Of course, the company will need to be showing double digit yoy quarterly growth which it should do as the rest of its pipeline and technology is brought to market.
Intermune was bought out and those investors cashed out when I think the company could've kept growing on its own. For sure it was a nice buyout price but they were breaking into a solid ride up and now the company belongs to Roche.
I think the company will trade in the $7-13 range until early next year as they get the cash infusion in place and towards building out the execution plan. Once they start showing revenue, the price will start rising. As new products are brought to market and realizing revenue, watch out!!
Wrong direction Lord. We need for the Shorts to drop this stock to fifty cents. Please hear my prayers.
I promise to buy all of that I can and retire a multi-millionaire in a year. I will then be a billionaire in ten years.
Please Lord.....let the Shorts do their duty. Drop it as far as you can.
I'm sure Shorts have some control. However, this looks more like short term greed and fear by the day and swing traders. Bills are coming due so they can't risk too much in immediate short term. That's how you lose your money quickly. I look forward to the next 1-5 years :)
Yes! And thankfully MNKD told Pfizer to take a hike. Those Pfizer folks can take their old inventory and sell them as bongs to third world countries. Lol.
It would be great for the short hedgies to drop the price down further so I can scoop up more shares and tuck them away with a $300 sell limit. At a $1 per share, I will be counting my tens of millions in a few years. What a blessing that would be.
Exubera should have been sold in the sixties and seventies as the Bong that could inhale insulin and dope at the same time. Look at how dumb Pfizer was to think that someone is going to be carrying around a junk contraption that resembled a bong to inhale insulin. The person would get pulled over at every corner, be leered at in every public place, not to mention how you carry this thing around without a backpack. I don't care if you smoke your dope and want to knock your own brains out, just don't get out on the road and hurt innocent people like me.
Dreamboat is the real deal, it's safe, it's easily portable, and it's effective. I think the Short Hedge Fund moron who said MNKD should be a $1/share should be shorting Pfizer instead. But it just goes to show you that stupids follow the other dolts to poverty.
mouth against Sanofi. He thinks he's a Hercules in the market however he probably will die broke and homeless in a New York back alley. You just have to laugh at these buffoons. They huffed, they puffed (funny stuff I suppose) and they tried to blow the brick house down. Now the door is nailed shut and Affrezza has secured the best worldwide deal that we could imagine. If you can be patient, wait a couple of years and you will be richly rewarded. You don't see the Hedgie Short Wedgies hanging around the Regeneron board.
LOL at the bonehead Shorties.....hahahahahahahah!
SNY may opt to buy a large lot of shares in MNKD like they did with Regeneron. It was rumored that Regeneron may have been bought out but SNY isn't the type of company that would force such option. They will secure their interests though which means buying enough of MNKD to put a few directors on the board and get licensing rights. SNY is good in worldwide sales/marketing. They discovered that leaving R&D as an external function works well for them since they haven't been good at internal R&D.
I've tucked the shares away for the next several years. They'll be worth 15 times or more in a few years if the company is not bought out. A good return versus the alternatives (being a short of this company or hanging onto a bank CD).
Yeah, ok. How about you google the Regeneron/Sanofi deal and see how that series of deals was structured. Regeneron reduced its risk tremendously and is enjoying nice fat revenue streams and a guaranteed partner for all future product development. Mannkind will also benefit from such relationship and now is freed up to bring future product and technology to the market. Sanofi is screaming for new product patent lines. Mannkind has cash in the bank (no dilution) and will lower expenses over future quarters.
Keep shorting. Wait a few quarters from now and eat your words. And don't forget that a buyout is always lurking. You'll wake up one day and find out that you owe your retirement fund to your mistake.
Sanofi could move in on Mannkind at this low pps. They bought big into Regeneron but did not acquire once Regeneron share price soared. Regeneron got a sweetheart deal in a 50/50 profit share and Sanofi picking up all costs. Mannkind could see a similar type deal in the future if they aren't bought out first. I do agree that the stock price will start going up steadily. I figure $100/share in a year or two. Sanofi needs to get afrezza into the marketplace soon to meet their 2015 product goal.
This is not good for shorts. They will catapult the share price more quickly once they realize their greedy mistake.
Quit lying. Several big pharmas wanted afrezza. Sanofi happens to be a giant pharma that wants to build out its revenue portfolio and was an awesome strategic fit for Mannkind. With the $150 million upfront payment (not a loan), Mannkind can focus on Danbury production and develop its other product and solution lines. What an awesome play. This could be better than Regeneron. Tuck away the shares and watch for the $100 pps mark in a year.
Restate - Sanofi makes an offer for $60/share. A year from now I think buyout offers will be coming in much higher.
If you actually follow the company's progress, Afrezza is just a piece of their R&D portfolio. They are developing other marketable solutions and let's not forget their technosphere solutions which are highly in demand. There is nothing in this agreement that prevents MNKD from being bought out. In fact, this is just another awesome development in the company's success. Sharing the risk and reward is one of Al's best moves.
If you buy now, you should see $15-20/PPS in short order. Get greedy for the 50-100% short term gains. Afrezza is going to market and Mannkind will collect on every turn. I wouldn't be surprised if Sanofi doesn't make an offer for $60/share.
Mannkind is definitely ramping up production. If the company does not engage in a buyout then I suppose they can partner an exclusive on the technosphere/affrezza solution to begin with and keep technosphere as a future solution to other medical conditions. I am holding long into the future because I think this company will continue to expand on its intellectual development and will be a powerhouse within a couple of short years. Every diabetic that I've spoken with is eager to try the inhalant. No wonder that the competition is trying hard to catch up to Mannkind but they will not succeed in getting the marketshare that Mannkind will get.
I look forward to the cc on Monday primarily for updates on development. As noted earlier, the company realizes that they need some time to get operations in line with execution so hang tight, enjoy the rest of the summer, and look forward to some nice gains in the next year and on.